Peroxisome proliferator-activated receptors (
PPAR),
ligand-activated
transcription factors, belong to the
nuclear hormone receptor superfamily regulating expression of genes involved in different aspects of lipid metabolism,
inflammation and cardiac energy production. Activation of
PPAR-α
isoform by its natural
ligands,
fatty acids (FA) and
eicosanoids, promotes mitochondrial FA oxidation as the primary
ATP-generating pathway. On the other hand,
PPAR-γ regulates
lipid anabolism or storage, while, until recently, the function of
PPAR-β/δ has been less explored. Under conditions associated with acute or chronic
oxygen deprivation,
PPAR-α modulates expression of genes that determine substrate switch (FA vs.
glucose) aimed at maintenance of basic cardiac function. Although
PPAR-α and
PPAR-γ synthetic agonists, hypolipidemic and
antidiabetic drugs, have been reported to protect the heart against
ischemia/reperfusion injury, it is still a matter of debate whether
PPAR activation plays a beneficial or detrimental role in myocardial response to
ischemia, in particular, in pathological conditions. This article reviews some findings demonstrating the impact of
PPAR activation on cardiac resistance to
ischemia in normal and pathologically altered heart. Specifically, it addresses the issue of susceptibility to
ischemia in the diabetic myocardium, with particular regards to the role of
PPAR. Finally, involvement of
PPAR in the mechanisms of
lipid-independent cardioprotective effects of some
hypolipidemic drugs is also discussed.